Autopsy report · NCT05720052

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study is terminated due to major protocol revisions.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 10 months before it stopped.
8 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: MingSight Pharmaceuticals, Inc
Sponsor type: Industry
Conditions: Relapsed or Refractory B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Interventions: MS-553
Participants: 8
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.